Drug interactions
Lenvatinib + Regorafenib
Severity: Moderate
Lenvatinib and Regorafenib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Regorafenib may inhibit BCRP and increase lenvatinib exposure. Both agents cause hypertension, hepatotoxicity and bleeding, so additive toxicity is also a concern.
What this interaction means in plain words
Lenvatinib and Regorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Lenvatinib belongs to Oncology; Regorafenib belongs to Oncology.
Why it happens
Regorafenib inhibits BCRP transport and both drugs share overlapping pharmacodynamic toxicities.
What to do
Avoid combining these kinase inhibitors where possible. If combined, monitor blood pressure, liver function and proteinuria, and reduce doses for toxicity.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lenvatinib and Regorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Regorafenib
Other interactions of Lenvatinib
- Amiodarone + Lenvatinib Major
- Amisulpride + Lenvatinib Major
- Asenapine + Lenvatinib Major
- Chlorpromazine + Lenvatinib Major
- Donepezil + Lenvatinib Major
- Haloperidol + Lenvatinib Major
Frequently asked questions
Can I take Lenvatinib with Regorafenib?
MediHelp rates the interaction as moderate. Lenvatinib and Regorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Regorafenib may inhibit BCRP and increase lenvatinib exposure. Both agents cause hypertension, hepatotoxicity and bleeding, so additive toxicity is also a concern.
How serious is the interaction between Lenvatinib and Regorafenib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining these kinase inhibitors where possible. If combined, monitor blood pressure, liver function and proteinuria, and reduce doses for toxicity.
What other medicines interact with Regorafenib?
MediHelp also lists interactions of Regorafenib with, for example, Apalutamide, Atazanavir, Carbamazepine. The full list is on the Regorafenib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
